M-s Tsao
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.
Journal: Clinical lung cancer
Published: April 09, 2024
Standardizing biomarker testing for Canadian patients with advanced lung cancer.
Journal: Current oncology (Toronto, Ont.)
Published: March 07, 2018
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Journal: Cancer treatment reviews
Published: May 09, 2017
TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.
Journal: Oncogene
Published: August 19, 2016
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 23, 2016
Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 20, 2016
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Journal: British journal of cancer
Published: May 03, 2015
Training in molecular cytopathology.
Journal: Cytopathology : official journal of the British Society for Clinical Cytology
Published: May 29, 2013
Fibroblast growth factor inhibitors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 25, 2010
Last Updated: 09/26/2026